Compare CHD & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHD | PODD |
|---|---|---|
| Founded | 1846 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6B | 22.1B |
| IPO Year | N/A | 2007 |
| Metric | CHD | PODD |
|---|---|---|
| Price | $84.61 | $304.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | $101.43 | ★ $359.00 |
| AVG Volume (30 Days) | ★ 2.4M | 765.6K |
| Earning Date | 10-31-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | ★ 42.14 | N/A |
| EPS | 3.17 | ★ 3.45 |
| Revenue | ★ $6,141,000,000.00 | $2,521,800,000.00 |
| Revenue This Year | $2.52 | $32.55 |
| Revenue Next Year | $4.02 | $20.39 |
| P/E Ratio | ★ $26.67 | $88.24 |
| Revenue Growth | 1.45 | ★ 27.11 |
| 52 Week Low | $81.33 | $230.05 |
| 52 Week High | $116.46 | $354.88 |
| Indicator | CHD | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 40.94 |
| Support Level | $83.37 | $303.20 |
| Resistance Level | $84.86 | $317.34 |
| Average True Range (ATR) | 1.35 | 13.12 |
| MACD | 0.18 | -2.82 |
| Stochastic Oscillator | 80.51 | 3.14 |
Church & Dwight is the leading global producer of baking soda. Its portfolio extends beyond its legacy category to include laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its brands also include Batiste, OxiClean, Vitafusion, Hero, and TheraBreath, which together with Arm & Hammer constitute around 70% of its annual sales and profits. Most recently, the firm added Touchland and its hand sanitizer business to its fold. Even as it works to expand its product reach, Church & Dwight still derives around 80% of its sales from its home market in the US.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.